Enduralife + Latitude + HeartLogic = 360CRT

 

It is more important than ever for physicians to monitor
and manage their heart failure patients.

Heart Failure diagnostics, battery longevity, and remote management systems from Boston Scientific combine to offer 360-degree clinical care and reduce hospitalizations and hospital visits. 

 

 

66% of patients are nervous or very nervous about visiting their HCP
CRT-D avoidable change-outs for patients >70 years old, using a CRT-D with nine-year longevity1
90% of patients seek reassurance that their HCP office/hospital is clean, safe and taking precautions
Patients desire a longer-lasting device2
85% of patients are interacting with their HCP less frequently than before COVID-19
Reduction in hospitalizations associated with HeartLogic™3
Source: Boston Scientific May 2020 US Patient Research

 

 

Focus Enduralife

 

LONGEVITY


The patient's life is improved by longevity by requiring fewer replacements:

  • Assuring that infection and complications are minimized
  • Reducing the cost of therapy
  • Enhancing patient therapy through battery optimization
  • Improving patients' quality of life
Longevity Device

EnduraLife™ Battery Technology was introduced by Boston Scientific in 2007 and has been validated by nine studies published since 2013.4-12 Boston Scientific offers the longest-lasting devices on the market.13, 14

 

Outperforming the Competition

EnduraLife™ Battery Technology has the largest usable battery capacity vs. Medtronic and Abbott.15

Real-world Data

Boston Scientific defibrillators vs. competitors: after 7-year Product Performance Report data.

66% of patients are nervous or very nervous about visiting their HCP
BOSTON SCIENTIFIC
CRT-Ds still in service14
66% of patients are nervous or very nervous about visiting their HCP
ABBOTT
CRT-Ds still in service16
66% of patients are nervous or very nervous about visiting their HCP
MEDTRONIC
CRT-Ds still in service17

SMART Multi-Site Pacing (MSP)18

Based on the results of the SMART-MSP study conducted in the US with 584 patients, Boston Scientific Multi-Site Pacing is associated with improved clinical response in non-responders to CRT therapy, as well as minimal impact on battery life.
 

Multi-Site Pacing (MSP) has a minimal impact on battery longevity

EnduraLife™ Competition Graph

Discover more on EnduraLife Battery Technology

DISCOVER MORE ON DEVICE LONGEVITY

 

 

Discover Boston Scientific Patient Management solutions

 

REMOTE PATIENT MANAGEMENT


Remote device monitoring is more relevant and useful than ever during the COVID-19 pandemic. It will help you:

  • Identify clinical events and device anomalies in patients with cardiac implantable defibrillators who's in-person visit was canceled.
  • Allow physicians to monitor disease progression remotely and to modify patients’ treatment appropriately (except for programming changes).
  • When patients feel more empowered in the remote monitoring process, they will become more invested in improving their health. Thus, we should feel confident to use remote device monitoring for patients with cardiac implantable defibrillators during the COVID-19 pandemic.19
Remote Patient Management

In the context of the Covid-19 pandemic, leveraging remote patient monitoring technology will help eliminate unnecessary patient contact, while reducing the burden on in-clinic follow-up.

In the context of the Covid-19 pandemic, leveraging remote patient monitoring technology will help eliminate unnecessary patient contact, while reducing the burden on in-clinic follow-up.
  • "Is recommended that HF patients are enrolled in a multidisciplinary HF management programme to reduce the risk of HF hospitalisation and mortality."20

  • "Remote device management is recommended to reduce number of in-office follow-up in patients."20


2021 ESC Guidelines21, 22 for the management of chronic Heart Failure and implantable devices. Recommendations have now the highest level of evidence: Class 1, level of evidence A
In the context of the Covid-19 pandemic, leveraging remote patient monitoring technology will help eliminate unnecessary patient contact, while reducing the burden on in-clinic follow-up.

 

 

Discover Boston Scientific Patient Management solutions

DISCOVER MORE ON REMOTE PATIENT MANAGEMENT PORTFOLIO

 

 

Discover how HeartLogic™ can help you in your daily practice

 

HEART FAILURE DIAGNOSTIC


In the COVID-19 pandemic, and beyond, HeartLogic offers a personalised, remote heart failure diagnostic and monitoring solution. Using multiple, novel physiologic sensors with high sensitivity and low-alert burden, it’s validated to provide weeks of advance notice for detecting early signs of worsening heart failure.


HeartLogic is clinically validated to provide weeks of advance notice for detecting early signs of worseningheart failure23

70% Sensitivity in detecting heart failures events
SENSITIVITY
in detecting heart failure events23
Median of 34 days advance notice of heart failure wersening
DAYS ADVANCE NOTICE
of heart failure worsening23
<2 total alerts per patient per year
TOTAL ALERTS
per patient per year23


Integration into clinical practice

In the MANAGE-HF Phase 1 Study24, HeartLogic is associated with:

  • a 67% reduction in HF hospitalisation rate
  • A reduction of N-terminal pro b-type natriuretic peptide (NTproBNP) levels
More rapid recovery of HeartLogic index
MORE RAPID RECOVERY
of HeartLogic index
Lower NTproBNP Levels
LOWER
NTproBNP Levels
67% reduction in Hospitalisation Associated with HeartLogic
67% REDUCTION
in Hospitalisation Associated with HeartLogic

 

Discover how HeartLogic™ can help you in your daily practice

DISCOVER MORE ON HEART FAILURE DIAGNOSTIC

 

Top